These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 33754956)

  • 1. Access to OUD Treatment and Maintenance of Sobriety amid the COVID-19 Pandemic.
    Rahman F; Evans N; Bernhardt J
    Subst Use Misuse; 2021; 56(7):1005-1009. PubMed ID: 33754956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leveraging pharmacists to maintain and extend buprenorphine supply for opioid use disorder amid COVID-19 pandemic.
    Peckham AM; Ball J; Colvard MD; Dadiomov D; Hill LG; Nichols SD; Tallian K; Ventricelli DJ; Tran TH
    Am J Health Syst Pharm; 2021 Mar; 78(7):613-618. PubMed ID: 33411894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient Barriers and Facilitators to Medications for Opioid Use Disorder in Primary Care.
    Tofighi B; Williams AR; Chemi C; Suhail-Sindhu S; Dickson V; Lee JD
    Subst Use Misuse; 2019; 54(14):2409-2419. PubMed ID: 31429351
    [No Abstract]   [Full Text] [Related]  

  • 4. Response to coronavirus 2019 in Veterans Health Administration facilities participating in an implementation initiative to enhance access to medication for opioid use disorder.
    Gustavson AM; Gordon AJ; Kenny ME; McHenry H; Gronek J; Ackland PE; Hagedorn HJ
    Subst Abus; 2020; 41(4):413-418. PubMed ID: 32936695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of COVID-19 on healthcare delivery for people who use opioids: a scoping review.
    Alexander K; Pogorzelska-Maziarz M; Gerolamo A; Hassen N; Kelly EL; Rising KL
    Subst Abuse Treat Prev Policy; 2021 Aug; 16(1):60. PubMed ID: 34372900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mobile Telemedicine for Buprenorphine Treatment in Rural Populations With Opioid Use Disorder.
    Weintraub E; Seneviratne C; Anane J; Coble K; Magidson J; Kattakuzhy S; Greenblatt A; Welsh C; Pappas A; Ross TL; Belcher AM
    JAMA Netw Open; 2021 Aug; 4(8):e2118487. PubMed ID: 34448869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of office-based buprenorphine treatment outcomes in Bronx community clinics before versus during the COVID-19 pandemic.
    Cunningham CO; Khalid L; Deng Y; Torres-Lockhart K; Masyukova M; Thomas S; Zhang C; Lu T
    J Subst Abuse Treat; 2022 Apr; 135():108641. PubMed ID: 34863608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. "How will I get my next week's script?" Reactions of Reddit opioid forum users to changes in treatment access in the early months of the coronavirus pandemic.
    Krawczyk N; Bunting AM; Frank D; Arshonsky J; Gu Y; Friedman SR; Bragg MA
    Int J Drug Policy; 2021 Jun; 92():103140. PubMed ID: 33558165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medication treatment for opioid use disorder and community pharmacy: Expanding care during a national epidemic and global pandemic.
    Cochran G; Bruneau J; Cox N; Gordon AJ
    Subst Abus; 2020; 41(3):269-274. PubMed ID: 32697171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics and correlates of U.S. clinicians prescribing buprenorphine for opioid use disorder treatment using expanded authorities during the COVID-19 pandemic.
    Jones CM; Diallo MM; Vythilingam M; Schier JG; Eisenstat M; Compton WM
    Drug Alcohol Depend; 2021 Aug; 225():108783. PubMed ID: 34049102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Designing and Evaluating COVID-19 Protocols for an Office-Based Opioid Treatment Program in an Urban Underserved Setting.
    O'Gurek DT
    J Am Board Fam Med; 2021 Feb; 34(Suppl):S136-S140. PubMed ID: 33622828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The intertwined expansion of telehealth and buprenorphine access from a prescriber hub.
    Moore DT; Wischik DL; Lazar CM; Vassallo GG; Rosen MI
    Prev Med; 2021 Nov; 152(Pt 2):106603. PubMed ID: 33974959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implementing a low-threshold audio-only telehealth model for medication-assisted treatment of opioid use disorder at a community-based non-profit organization in Washington, D.C.
    Yeo EJ; Kralles H; Sternberg D; McCullough D; Nadanasabesan A; Mayo R; Akselrod H; Catalanotti J
    Harm Reduct J; 2021 Dec; 18(1):127. PubMed ID: 34886850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perceived risk, attitudes, and behavior of cigarette smokers and nicotine vapers receiving buprenorphine treatment for opioid use disorder during the COVID-19 pandemic.
    Streck JM; Kalkhoran S; Bearnot B; Gupta PS; Kalagher KM; Regan S; Wakeman S; Rigotti NA
    Drug Alcohol Depend; 2021 Jan; 218():108438. PubMed ID: 33271434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Buprenorphine maintenance treatment in patients with opioid use disorder diagnosed with COVID-19.
    Frost M
    J Opioid Manag; 2020; 16(6):405-407. PubMed ID: 33428187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An examination of telehealth policy impacts on initial rural opioid use disorder treatment patterns during the COVID-19 pandemic.
    Hughes PM; Verrastro G; Fusco CW; Wilson CG; Ostrach B
    J Rural Health; 2021 Jun; 37(3):467-472. PubMed ID: 33720447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low Threshold Telemedicine-based Opioid Treatment for Criminal Justice Involved Adults During the COVID-19 Pandemic: A Case Report.
    Flavin L; Tofighi B; Krawczyk N; Schatz D; McNeely J; Butner J
    J Addict Med; 2022 Jan-Feb 01; 16(1):e59-e61. PubMed ID: 35120069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of opioid use disorder during COVID-19: Experiences of clinicians transitioning to telemedicine.
    Uscher-Pines L; Sousa J; Raja P; Mehrotra A; Barnett M; Huskamp HA
    J Subst Abuse Treat; 2020 Nov; 118():108124. PubMed ID: 32893047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Take home injectable opioids for opioid use disorder during and after the COVID-19 Pandemic is in urgent need: a case study.
    Oviedo-Joekes E; MacDonald S; Boissonneault C; Harper K
    Subst Abuse Treat Prev Policy; 2021 Mar; 16(1):22. PubMed ID: 33673847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early innovations in opioid use disorder treatment and harm reduction during the COVID-19 pandemic: a scoping review.
    Krawczyk N; Fawole A; Yang J; Tofighi B
    Addict Sci Clin Pract; 2021 Nov; 16(1):68. PubMed ID: 34774106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.